Valeant Pharmaceuticals International Inc (VRX): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Valeant Pharmaceuticals International ( VRX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.4%. By the end of trading, Valeant Pharmaceuticals International rose $1.44 (1.4%) to $104.73 on light volume. Throughout the day, 593,104 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,225,600 shares. The stock ranged in a price between $102.73-$104.79 after having opened the day at $103.14 as compared to the previous trading day's close of $103.29. Other companies within the Drugs industry that increased today were: Cardium Therapeutics ( CXM), up 27.8%, Zalicus ( ZLCS), up 26.8%, Rockwell Medical ( RMTI), up 16.9% and ZIOPHARM Oncology ( ZIOP), up 13.8%.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $34.5 billion and is part of the health care sector. Shares are up 73.5% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and generally higher debt management risk.

On the negative front, Nektar Therapeutics ( NKTR), down 23.9%, Cellular Dynamics International ( ICEL), down 10.7%, TG Therapeutics ( TGTX), down 7.6% and Chembio Diagnostics ( CEMI), down 6.4% , were all laggards within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers